ES2130167T3 - Un sistema para la eliminacion mejorada in vivo de agentes de diagnostico y/o agentes terapeuticos por agotamiento extracorpores de los agentes. - Google Patents

Un sistema para la eliminacion mejorada in vivo de agentes de diagnostico y/o agentes terapeuticos por agotamiento extracorpores de los agentes.

Info

Publication number
ES2130167T3
ES2130167T3 ES92903020T ES92903020T ES2130167T3 ES 2130167 T3 ES2130167 T3 ES 2130167T3 ES 92903020 T ES92903020 T ES 92903020T ES 92903020 T ES92903020 T ES 92903020T ES 2130167 T3 ES2130167 T3 ES 2130167T3
Authority
ES
Spain
Prior art keywords
agents
extracorports
exhaustion
vivo
diagnostic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES92903020T
Other languages
English (en)
Inventor
Rune Nilsson
Lars Lindgren
Kristina Norrgren
Bengt Sandberg
Hans-Olof Sjogren
Sven-Erik Strand
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SJOGREN HANS OLOF
STRAND SVEN ERIK
Original Assignee
SJOGREN HANS OLOF
STRAND SVEN ERIK
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SJOGREN HANS OLOF, STRAND SVEN ERIK filed Critical SJOGREN HANS OLOF
Application granted granted Critical
Publication of ES2130167T3 publication Critical patent/ES2130167T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells
    • A61K47/6893—Pre-targeting systems involving an antibody for targeting specific cells clearing therapy or enhanced clearance, i.e. using an antibody clearing agents in addition to T-A and D-M
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells
    • A61K47/6899—Antibody-Directed Enzyme Prodrug Therapy [ADEPT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/36—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
    • A61M1/3679—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits by absorption
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00—Preparations for testing in vivo

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Vascular Medicine (AREA)
  • Nanotechnology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Medical Informatics (AREA)
  • Molecular Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biotechnology (AREA)
  • Cardiology (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • External Artificial Organs (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

SE DESCRIBE UN METODO Y UN SISTEMA PARA REDUCIR EN ANFITRIONES VERTEBRADOS, LOS NIVELES NO OBJETIVOS DE MOLECULAS ESPECIFICAS DESTINADAS AL DIAGNOSTICO Y/O APLICACIONES TERAPEUTICAS, EN DONDE DICHAS MOLECULAS SE ADMINISTRAN A UN ANFITRION VERTEBRADO Y SE MANTIENEN EN EL MISMO POR UN CIERTO TIEMPO, PARA QUE SE CONCENTREN EN EL OBJETIVO POR AGREGACION AL MISMO. LAS MOLECULAS QUE NO SE AGREGAN AL OBJETIVO SE EXTRAEN DEL SISTEMA DE CIRCULACION SANGUINEA O AL MENOS SE REDUCEN A UNA CONCENTRACION MENOR, PASANDO LA SANGRE A TRAVES DE UN DISPOSITIVO EXTRACORPOREO.
ES92903020T 1991-01-17 1992-01-15 Un sistema para la eliminacion mejorada in vivo de agentes de diagnostico y/o agentes terapeuticos por agotamiento extracorpores de los agentes. Expired - Lifetime ES2130167T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9100142A SE9100142L (sv) 1991-01-17 1991-01-17 En metod och ett system foer foerbaettrad in vivo reducering av diagnostiska och/eller terapeutiska substanser medelst extrakorporeal borttagning, och anvaendandet av naemnda substanser foer detta aendamaal

Publications (1)

Publication Number Publication Date
ES2130167T3 true ES2130167T3 (es) 1999-07-01

Family

ID=20381639

Family Applications (1)

Application Number Title Priority Date Filing Date
ES92903020T Expired - Lifetime ES2130167T3 (es) 1991-01-17 1992-01-15 Un sistema para la eliminacion mejorada in vivo de agentes de diagnostico y/o agentes terapeuticos por agotamiento extracorpores de los agentes.

Country Status (10)

Country Link
US (2) US6251394B1 (es)
EP (1) EP0567514B1 (es)
JP (1) JP3471352B2 (es)
AT (1) ATE178214T1 (es)
CA (1) CA2100256C (es)
DE (1) DE69228802T2 (es)
DK (1) DK0567514T3 (es)
ES (1) ES2130167T3 (es)
SE (1) SE9100142L (es)
WO (1) WO1992012730A1 (es)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6416738B1 (en) 1973-12-07 2002-07-09 Neorx Corporation Pretargeting methods and compounds
US6075010A (en) * 1992-06-09 2000-06-13 Neorx Corporation Small molecular weight ligand-hexose containing clearing agents
US5474772A (en) * 1989-08-02 1995-12-12 Cobe Laboratories, Inc. Method of treatment with medical agents
US5911969A (en) 1992-06-09 1999-06-15 Neorx Corporation Pretargeting protocols for enhanced localization of active agents to target sites
US6358490B2 (en) 1992-06-09 2002-03-19 Neorx Corporation Three-step pretargeting methods and compounds
US6217869B1 (en) 1992-06-09 2001-04-17 Neorx Corporation Pretargeting methods and compounds
JPH09506106A (ja) * 1993-12-07 1997-06-17 ネオルクス コーポレーション プレターゲティング方法及び化合物
US6015897A (en) * 1993-12-07 2000-01-18 Neorx Corporation Biotinamido-n-methylglycyl-seryl-o-succinamido-benzyl dota
AU2191795A (en) * 1994-03-23 1995-10-09 Alexion Pharmaceuticals, Inc. Method for reducing immune and hemostatic dysfunctions during extracorporeal circulation
US6908903B1 (en) 1994-12-07 2005-06-21 Aletheon Pharmaceuticals, Inc. Cluster clearing agents
US6172045B1 (en) 1994-12-07 2001-01-09 Neorx Corporation Cluster clearing agents
WO1997025069A1 (en) * 1996-01-11 1997-07-17 Techniclone, Inc. Antibodies with reduced net positive charge
US20010023288A1 (en) 1999-07-07 2001-09-20 Wilbur D. Scott Trifunctional reagent for conjugation to a biomolecule
SI1049499T1 (en) * 1998-01-20 2004-04-30 Mitra Medical Technology Ab An apparatus for use in connection with removal of elements, especially exogenous antibodies, from blood or plasma
US6533734B1 (en) * 1999-06-11 2003-03-18 The Board Of Trustees Of The University Of Illinois Time-integrated sampler of bodily fluid
IT1310933B1 (it) * 1999-11-16 2002-02-27 Luigi Benatti Macchina multifunzionale per il monitoraggio ed il controllo diterapie locoregionali in oncologia.
SE0002287D0 (sv) 2000-06-16 2000-06-16 Department Of Radiation Oncolo Biotinderivat
BR0111726A (pt) * 2000-06-16 2003-05-27 Mitra Medical Technology Ab Derivados de biotina
US7682793B2 (en) * 2001-08-01 2010-03-23 Chauhan Anil K Immune complexes
WO2003090781A1 (en) * 2002-04-23 2003-11-06 Meir Strahilevitz Methods and devices for targeting a site in a mammal and for removing species from a mammal
US20040044300A1 (en) * 2002-09-03 2004-03-04 Donnie Rudd Method of replenishing cells damaged by treatment for cancer
US20040077985A1 (en) * 2002-09-03 2004-04-22 Donnie Rudd Method of replenishing cells damaged by treatment for cancer
US20040208865A1 (en) * 2003-02-12 2004-10-21 Chauhan Anil K. Immune complexes
US20080075704A1 (en) * 2005-02-28 2008-03-27 Wolf David A Method of providing readily available cellular material derived from peripheral blood, and a composition thereof
US20060193839A1 (en) * 2005-02-28 2006-08-31 Donnie Rudd Method of providing readily available cellular material derived from peripheral blood, and a composition thereof
US20110014151A1 (en) * 2006-01-11 2011-01-20 Biotech Igg Ab Macromolecule conjugate
WO2012142180A1 (en) * 2011-04-12 2012-10-18 Tianxin Wang Methods to detect and treat diseases
US9549953B2 (en) * 2011-12-08 2017-01-24 Eliaz Therapeutics, Inc. Galectin-3 plasmapheresis therapy
MX356107B (es) 2012-02-16 2018-05-15 Atyr Pharma Inc Histidil-arnt sintetasas para tratar enfermedades autoinmunes e inflamatorias.
CN105378075B (zh) 2013-03-15 2022-04-05 Atyr 医药公司 组氨酰-trna合成酶-fc缀合物
CN110536694A (zh) 2017-04-20 2019-12-03 Atyr 医药公司 用于治疗肺部炎症的组合物和方法

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4375414A (en) 1971-05-20 1983-03-01 Meir Strahilevitz Immunological methods for removing species from the blood circulatory system and devices therefor
US4371515A (en) 1978-12-26 1983-02-01 E-Y Laboratories, Inc. Method for forming an isolated lectin-immunological conjugate
US4223672A (en) 1979-02-08 1980-09-23 Baxter Travenol Laboratories, Inc. Variable volume plasma treatment chamber for an apparatus for the extracorporeal treatment of disease
US4215688A (en) 1979-02-09 1980-08-05 Baxter Travenol Laboratories, Inc. Apparatus for the extracorporeal treatment of disease
US4350156A (en) 1980-05-29 1982-09-21 Japan Foundation For Artificial Organs Method and apparatus for on-line filtration removal of macromolecules from a physiological fluid
US4824432A (en) 1981-03-24 1989-04-25 S.V.S. Laboratories, Inc. Method for treating AIDS and other immune deficiencies and immune disorders
US4687808A (en) 1982-08-12 1987-08-18 Biospecific Technologies, Inc. Activation of biocompatible polymers with biologicals whose binding complements are pathological effectors
CA1221307A (en) 1982-12-02 1987-05-05 Nobutaka Tani Adsorbent and process for preparing the same
CA1236738A (en) 1983-06-01 1988-05-17 Mark R. Honard Therapeutic device
US4551435A (en) 1983-08-24 1985-11-05 Immunicon, Inc. Selective removal of immunospecifically recognizable substances from solution
US4863713A (en) 1986-06-23 1989-09-05 The Board Of Trustees Of Leland Stanford Jr. Univ. Method and system for administering therapeutic and diagnostic agents
US4877599A (en) 1986-11-10 1989-10-31 New England Deaconess Hospital Corporation Detection of vascular disease with labelled antibodies
US5122112A (en) * 1986-11-21 1992-06-16 Imre Corporation Antigen-specific removal of circulating immune complexes
US4800016A (en) 1986-11-24 1989-01-24 The University Of Michigan Extracorporeal blood de-heparinization system
DE3705637A1 (de) * 1987-02-21 1988-09-29 Bissendorf Peptide Gmbh Vorrichtung zur entfernung von lokal applizierten wirkstoffen gegen solide tumoren
US4846786A (en) 1987-04-30 1989-07-11 Massachusetts Institute Of Technology Bioreactor containing suspended, immobilized species
US4885207A (en) * 1987-07-13 1989-12-05 Uop Biocompatible protein or ligand immobilization system
US4865841A (en) 1987-10-23 1989-09-12 Imre Corporation Methods and compositions for transient elimination of humoral immune antibodies
US5069662A (en) * 1988-10-21 1991-12-03 Delcath Systems, Inc. Cancer treatment
US5149425A (en) 1988-11-09 1992-09-22 Chembiomed, Ltd. Affinity supports for hemoperfusion
AU648015B2 (en) * 1989-01-23 1994-04-14 Akzo N.V. Site specific in-vivo activation of therapeutic drugs
US5252466A (en) * 1989-05-19 1993-10-12 Biotechnology Research And Development Corporation Fusion proteins having a site for in vivo post-translation modification and methods of making and purifying them
US5474772A (en) * 1989-08-02 1995-12-12 Cobe Laboratories, Inc. Method of treatment with medical agents
EP0436717B1 (en) * 1989-08-02 2003-02-26 Mitra Medical Technology AB System for use in a method of therapeutic or diagnostic treatment
AU8366398A (en) 1998-07-07 2000-01-24 Department Of Radiation Oncology University Of Washington Trifunctional reagent for conjugation to a biomolecule

Also Published As

Publication number Publication date
JPH06504542A (ja) 1994-05-26
DK0567514T3 (da) 1999-10-18
CA2100256C (en) 2004-06-08
JP3471352B2 (ja) 2003-12-02
US6251394B1 (en) 2001-06-26
SE9100142D0 (sv) 1991-01-17
SE9100142L (sv) 1992-07-18
ATE178214T1 (de) 1999-04-15
US6723318B1 (en) 2004-04-20
EP0567514B1 (en) 1999-03-31
CA2100256A1 (en) 1992-07-18
DE69228802D1 (de) 1999-05-06
WO1992012730A1 (en) 1992-08-06
EP0567514A1 (en) 1993-11-03
DE69228802T2 (de) 1999-10-14

Similar Documents

Publication Publication Date Title
ES2130167T3 (es) Un sistema para la eliminacion mejorada in vivo de agentes de diagnostico y/o agentes terapeuticos por agotamiento extracorpores de los agentes.
BR9713979A (pt) Processos e aparelhos para a formação de imagem de um volume particular de tecido de planta ou de animal e para diagnóstico médico
ES2603086T3 (es) Uso de la daptomicina
MA52680A1 (fr) Méthodes de réduction du besoin de revascularisation artérielle périphérique chez un sujet traité par des statines
Öter et al. Evaluation of antibacterial efficiency of different root canal disinfection techniques in primary teeth
ES2139586T3 (es) Composiciones de contraste para rayos x utiles en diagnostico por imagenes.
ES2182853T3 (es) Regulacion de la dosis de un agente para el tratamiento del agua basado en tensiones del sistema operacional.
MX9204703A (es) Acidos n-acil-n-heterociclilalquilamino, proceso para su obtencion y composicion farmaceutica que los contiene.
AR022482A1 (es) Metodos y composiciones para usar en aplicaciones de perfusion
ES2085924T3 (es) Compuestos quelatantes y su utilizacion.
Tokuc et al. Bactericidal effect of 2780 nm Er, Cr: YSGG laser combined with 940 nm diode laser in Enterococcus faecalis elimination: a comparative study
ES2138613T3 (es) Derivado de espirooxatiolano-quinuclidina para el tratamiento del sindrome de sjoegren.
NO973459L (no) Vismut-forbindelser
SE8602743L (sv) Bruksferdiga injektionslosningar innehallande en antitumorantracyklinglykosid
AR001073A1 (es) Benzoilguanidinas basicamente sustituidas procedimientos para su preparación su empleo como medicamento o agente de diagnostico asi como medicamento que las contiene
EA200101240A1 (ru) Использование мелатонина в медицине
Spitznagel et al. Experimental pyelonephritis and hypertension in rats.
Uderhardt et al. Dynamic multiplex tissue imaging in inflammation research
Mendelssohn et al. Transmission of infection during withdrawal of blood
ES2038064B1 (es) Instalacion portatil de vacunacion aviar.
Sanders et al. Immunization of rats with irradiated Trypanosoma lewisi
BR8300068A (pt) Processo para o tratamento da acicla em ovelhas ou gado e emprego de gestagenio e th-rh ou seus analogos
Kew, MC, Bersohn, I., Peter, J., Wyndham, CH & Seftel Preliminary observations on the serum and cerebrospinal fluid enzymes in heatstroke
ES2032535T3 (es) Ensayos para la determinacion de componentes biologicamente acticos de fluidos biologicos.
BR9608147A (pt) Método para descontaminação microbiana de plaquetas sanguìneas.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 567514

Country of ref document: ES